Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ563563,5-0,09
KB908,59090,50
PKN97,1897,280,29
Msft1,67
Nokia4,7124,7180,41
IBM1,40
Daimler AG58,2758,291,87
PFE1,13
21.9.2018 9:26:01
Indexy online
AD Index online
select
AD Index online
 

  • 20.9.2018
GlycoMimetics (NASDAQ Cons)
Závěr k 20.9.2018 Změna (%) Změna (USD) Objem obchodů (ks)
14,46 -0,62 -0,09 446 920
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 21.9.2018
Popis společnosti
Obecné informace
Název společnostiGlycoMimetics Inc
TickerGLYC
Kmenové akcie:Ordinary Shares
RICGLYC.O
ISINUS38000Q1022
Poslední známé roční výsledky31.12.2017
Poslední známé čtvrtletní výsledky30.6.2018
Počet zaměstnanců k 31.12.2017 40
Akcie v oběhu k 8.8.2018 43 057 267
Počet akcionářů k 31.12.2017 32
MěnaUSD
Kontaktní informace
Ulice9708 Medical Center Dr
MěstoROCKVILLE
PSČ20850-3343
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon12 402 431 201
Fax12402431018

Business Summary: GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.
Financial Summary: BRIEF: For the six months ended 30 June 2018, GlycoMimetics Inc revenues was not reported. Net loss increased 42% to $22.8M. Higher net loss reflects researcg and development expense balanc increase of 59% to $17.5M (expense), General & Administrative Expe increase of 26% to $4.3M (expense), Stock-based Compensation in R&D increase of 36% to $853K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.64 to -$0.59.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSPharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 21.9.2018
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the BoardM. James Barrett75
President, Chief Executive Officer, Co-Founder, DirectorRachel King581.1.2003
Co-Founder, Senior Vice President, Chief Scientific Officer, DirectorJohn Magnani651.1.2003
Chief Financial OfficerBrian Hahn43
Senior Vice President - Clinical Development, Chief Medical OfficerHelen Thackray49